Interleukin-1 antagonism in type 1 diabetes of long duration

被引：10
|
作者：
Seelig, E. [1 ]
Timper, K. [1 ]
Falconnier, C. [2 ]
Stoeckli, R. [1 ]
Bilz, S. [3 ]
Oram, R. [4 ]
McDonald, T. J. [4 ]
Donath, M. Y. [1 ]
机构：
[1] Univ Basel Hosp, Dept Endocrinol Diabetol & Metab, Basel, Switzerland
[2] Kantonsspital Baselland, Med Univ Clin, Div Endocrinol Diabetol & Metab, Liestal, Switzerland
[3] Kantonsspital St Gallen, Clin Endocrinol Diabet Bone Dis & Metab, St Gallen, Switzerland
[4] Univ Exeter, NIHR Exeter Clin Res Facil, Exeter, Devon, England
来源：
DIABETES & METABOLISM | 2016年 / 42卷 / 06期
关键词：
INSULIN MICROSECRETORS;
D O I：
10.1016/j.diabet.2016.08.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：453 / 456
页数：4
相关论文
共 50 条
  • [1] INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM
    DINARELLO, CA
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 259 - 259
  • [2] INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM
    DINARELLO, CA
    [J]. BLOOD, 1991, 77 (08) : 1627 - 1652
  • [3] Interleukin-1 Antagonism: A Sturdy Companion for Immune Tolerance Induction in Type 1 Diabetes?
    Mandrup-Poulsen, Thomas
    [J]. DIABETES, 2014, 63 (06) : 1833 - 1835
  • [4] Interleukin-1 receptor antagonism
    NikolicPaterson, DJ
    Lan, HY
    Atkins, RC
    [J]. SEMINARS IN NEPHROLOGY, 1996, 16 (06) : 583 - 590
  • [5] An association between type 1 diabetes and the interleukin-1 receptor type 1 gene
    Metcalfe, KA
    Hitman, GA
    Pociot, F
    Bergholdt, R
    TuomilehtoWolf, E
    Tuomilehto, J
    Viswanathan, M
    Ramachandran, A
    Nerup, J
    Akerblom, HK
    Lounamaa, R
    Toivanen
    Fegerlund, A
    Flittner, M
    Gustafsson, B
    Haggqvist, C
    Hakulinen, A
    Herva, L
    Hiltunen, P
    Huhtamaki, T
    Huttunen, NP
    Huupponen, T
    Hyttinen, M
    Joki, T
    Jokisalo, R
    Kaar, ML
    Kallio, S
    Kaprio, EA
    Kaski, U
    Knip, M
    Laine, L
    Lappalainen, J
    Maenpaa, J
    Makela, AL
    Niemi, K
    Niiranen, A
    Nuuja, A
    Ojajarvi, P
    Otonkoski, T
    Pihlajamaki, K
    Pontynen, S
    Rajantie, J
    Sankala, J
    Schumacher, J
    Sillanpaa, M
    Stahlberg, MR
    Strahlmann, CH
    Uotila, T
    Vara, M
    Varimo, P
    [J]. HUMAN IMMUNOLOGY, 1996, 51 (01) : 41 - 48
  • [6] Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset
    Cabrera, Susanne M.
    Wang, Xujing
    Chen, Yi-Guang
    Jia, Shuang
    Kaldunski, Mary L.
    Greenbaum, Carla J.
    Mandrup-Poulsen, Thomas
    Hessner, Martin J.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 (04) : 1030 - 1046
  • [7] INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM IN SEPSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, AND SEPTIC SHOCK
    PRUITT, JH
    COPELAND, EM
    MOLDAWER, LL
    [J]. SHOCK, 1995, 3 (04): : 235 - 251
  • [8] MECHANISMS OF ANTAGONISM OF INTERLEUKIN-1-ALPHA BY SYNTHETIC INTERLEUKIN-1 BLOCKERS
    XIAO, JG
    SCHWADE, N
    CHIOU, GCY
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1995, 11 (03) : 369 - 378
  • [9] Expression of Interleukin-1 and Interleukin-1 Receptors Type 1 and Type 2 in Hodgkin Lymphoma
    Oelmann, Elisabeth
    Stein, Harald
    Berdel, Wolfgang E.
    Herbst, Hermann
    [J]. PLOS ONE, 2015, 10 (09):
  • [10] Interleukin-1 antagonists for diabetes
    Mandrup-Poulsen, Thomas
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (08) : 965 - 979
12345